These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 12643924)

  • 1. Structure-based de novo design of non-nucleoside adenosine deaminase inhibitors.
    Terasaka T; Nakanishi I; Nakamura K; Eikyu Y; Kinoshita T; Nishio N; Sato A; Kuno M; Seki N; Sakane K
    Bioorg Med Chem Lett; 2003 Mar; 13(6):1115-8. PubMed ID: 12643924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenosine deaminase inhibition enhances the inotropic response mediated by A1 adenosine receptor in hyperthyroid guinea pig atrium.
    Kemeny-Beke A; Jakab A; Zsuga J; Vecsernyes M; Karsai D; Pasztor F; Grenczer M; Szentmiklosi AJ; Berta A; Gesztelyi R
    Pharmacol Res; 2007 Aug; 56(2):124-31. PubMed ID: 17574432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adenosine deaminase inhibitors: synthesis and structure-activity relationships of imidazole analogues of erythro-9-(2-hydroxy-3-nonyl)adenine.
    Cristalli G; Eleuteri A; Franchetti P; Grifantini M; Vittori S; Lupidi G
    J Med Chem; 1991 Mar; 34(3):1187-92. PubMed ID: 2002459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Niacin prevents DNA strand breakage by adenosine deaminase inhibitors.
    Weitberg AB; Corvese D
    Biochem Biophys Res Commun; 1990 Mar; 167(2):514-9. PubMed ID: 2322239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of inhibition of adenosine deaminase by erythro-9-(2-hydroxy-3-nonyl)adenine in CBA mice.
    Lambe CU; Nelson DJ
    Biochem Pharmacol; 1982 Feb; 31(4):535-9. PubMed ID: 7066021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absorption and intestinal metabolism of purine dideoxynucleosides and an adenosine deaminase-activated prodrug of 2',3'-dideoxyinosine in the mesenteric vein cannulated rat ileum.
    Singhal D; Ho NF; Anderson BD
    J Pharm Sci; 1998 May; 87(5):569-77. PubMed ID: 9572907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenosine deaminase inhibitors: synthesis and biological evaluation of unsaturated, aromatic, and oxo derivatives of (+)-erythro-9-(2'S-hydroxy-3'R-nonyl)adenine [(+)-EHNA].
    Pragnacharyulu PV; Varkhedkar V; Curtis MA; Chang IF; Abushanab E
    J Med Chem; 2000 Nov; 43(24):4694-700. PubMed ID: 11101360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of the local inhibition of intestinal adenosine deaminase (ADA) by erythro-9-(2-hydroxy-3-nonyl)adenine: enhanced oral delivery of an ADA-activated prodrug for anti-HIV therapy.
    Singhal D; Anderson BD
    J Pharm Sci; 1998 May; 87(5):578-85. PubMed ID: 9572908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenosine deaminase inhibitors. Synthesis and biological activity of deaza analogues of erythro-9-(2-hydroxy-3-nonyl)adenine.
    Cristalli G; Franchetti P; Grifantini M; Vittori S; Lupidi G; Riva F; Bordoni T; Geroni C; Verini MA
    J Med Chem; 1988 Feb; 31(2):390-3. PubMed ID: 3339608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenosine deaminase inhibitors. Synthesis of deaza analogues of erythro-9-(2-hydroxy-3-nonyl)adenine.
    Antonini I; Cristalli G; Franchetti P; Grifantini M; Martelli S; Lupidi G; Riva F
    J Med Chem; 1984 Mar; 27(3):274-8. PubMed ID: 6699873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does adenosine deaminase inhibition protect ischemic myocardium?
    Gallagher KP; McClanahan TB; Martin BJ; Saganek LJ; Ignasiak DP; Mertz TE; Van Wylen DG; Vinten-Johansen J
    Adv Exp Med Biol; 1994; 370():291-4. PubMed ID: 7660911
    [No Abstract]   [Full Text] [Related]  

  • 12. Differential cardioprotection with selective inhibitors of adenosine metabolism and transport: role of purine release in ischemic and reperfusion injury.
    Abd-Elfattah AS; Jessen ME; Lekven J; Wechsler AS
    Mol Cell Biochem; 1998 Mar; 180(1-2):179-91. PubMed ID: 9546645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of adenosine deaminase from several sources by deaza derivatives of adenosine and EHNA.
    Lupidi G; Cristalli G; Marmocchi F; Riva F; Grifantini M
    J Enzyme Inhib; 1985; 1(1):67-75. PubMed ID: 3916912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sedative and electroencephalographic actions of erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA): relationship to inhibition of brain adenosine deaminase.
    Mendelson WB; Kuruvilla A; Watlington T; Goehl K; Paul SM; Skolnick P
    Psychopharmacology (Berl); 1983; 79(2-3):126-9. PubMed ID: 6405420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenosine deaminase inhibitors. Synthesis and biological evaluation of aralkyladenines (ARADS).
    Curtis MA; Varkhedkar V; Pragnacharyulu PV; Abushanab E
    Bioorg Med Chem Lett; 1998 Jul; 8(13):1639-42. PubMed ID: 9873405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The protonated form of 1-N6-etheno-[erythro-9-(2-hydroxy-3-nonyl)] adenine is identified at the active site of adenosine deaminase.
    Caiolfa VR; Gill D; Parola AH
    FEBS Lett; 1990 Jan; 260(1):19-22. PubMed ID: 2153576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced oral bioavailability of 2'- beta-fluoro-2',3'-dideoxyadenosine (F-ddA) through local inhibition of intestinal adenosine deaminase.
    DeGraw RT; Anderson BD
    Pharm Res; 2001 Sep; 18(9):1270-6. PubMed ID: 11683239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modifications of flexible nonyl chain and nucleobase head group of (+)-erythro-9-(2's-hydroxy-3's-nonyl)adenine [(+)-EHNA] as adenosine deaminase inhibitors.
    Kandalkar SR; Ramaiah PA; Joshi M; Wavhal A; Waman Y; Raje AA; Tambe A; Ansari S; De S; Palle VP; Mookhtiar KA; Deshpande AM; Barawkar DA
    Bioorg Med Chem; 2017 Oct; 25(20):5799-5819. PubMed ID: 28951094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetics of inhibition of calf intestinal adenosine deaminase by (+)- and (-)-erythro-9-(2-hydroxy-3-nonyl)adenine.
    Porter DJ; Abushanab E
    Biochemistry; 1992 Sep; 31(35):8216-20. PubMed ID: 1525161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of human T-cell rosette formation by the adenosine deaminase inhibitor erythro-9-(2-hydroxy-3-nonyl) adenine hydrochloride (EHNA).
    Lum CT; Schmidtke JR; Sutherland DE; Najarian JS
    Clin Immunol Immunopathol; 1978 Jul; 10(3):258-61. PubMed ID: 307473
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.